Cancer Immunology, Immunotherapy

, Volume 56, Issue 11, pp 1711–1721 | Cite as

Pattern of serum immunoreactivity against breast cancer cell lysates may predict severity of disease in breast cancer patients

  • Carlyle Hamsher
  • Anna M. Smith
  • Zia A. Dehqanzada
  • Steven Khoo
  • Sathibalan Ponniah
  • George E. Peoples
  • Maria Moroni
Original Article

Abstract

Humoral tumor-specific immunity has been investigated as a potential tool to identify tumor-associated antigens and evaluate cancer diagnosis and prognosis. Using SDS-PAGE and western blotting techniques we investigated the humoral immune response against tumor cell antigens in 36 breast cancer patients, 17 node-positive (NP) and 19 node-negative (NN). As a source of antigens, we prepared protein lysates from four breast cancer cell lines (AU565, BT474, MCF-7 and MDA-MB-231) which in vitro exhibit different features of invasion, estrogen receptor/progesterone receptor status and HER2/neu expression thereby potentially representing mild to aggressive forms of clinical disease. A higher number of immunocomplexes Ag–Ab were formed when serum from NN patients was immunoreacted against lysates from AU565 and MCF-7 in comparison to serum from NP patients (P < 0.01). BT474 cells were not a good antigenic source. MDA-MB-231 cells could not significantly discriminate between NN and NP patients since both groups showed higher amounts of reactivity against the lysate. However, comparative analysis of protein preparations purified from MCF-7 and MDA-MB-231 cells and immunodetected concomitantly with the same serum samples showed that serum from patients with cancers with worse prognosis (stage, nodality, HER2/neu and hormonal status) reacted more intensely to proteins purified from the relatively more invasive cell line MDA-MB-231 compared to MCF-7. These findings suggest that the study of serum antibody reactivity to antigens purified from breast cancer cell lines with different invasive properties should be further investigated for its potential in providing beneficial prognostic information in breast cancer.

Keywords

Breast cancer Serum antibody Immunoreactivity Tumor cell lysates 

Abbreviations

SDS-PAGE

Sodium dodecyl sulfate polyacrylamide gel

NP

Node-positive

NN

Node-negative

HER2/neu

Human epidermal growth factor receptor/neu

cDNA

Complementary deoxyribonucleic acid

SEREX

Serological expression cloning

SERPA

Serological proteome analysis

IR

Immunoreactivity

ELISA

Enzyme-linked immunosorbent assay

IgG

Immunoglobulin

TI

Total immunoreactivity

ANOVA

Analysis of variance

SE

Standard error

IP

Immunoreactivity pattern

Ag-Ab

Antigen-antibody

TIP

Total immunoreactivity pattern

References

  1. 1.
    Carr KM, Rosenblatt K, Petricoin EF, Liotta LA (2004) Genomic and proteomic approaches for studying human cancer: prospects for true patient-tailored therapy. Hum Genomics 1:134PubMedGoogle Scholar
  2. 2.
    Li G, Miles A, Line A, Rees RC (2004) Identification of tumour antigens by serological analysis of cDNA expression cloning. Cancer Immunol Immunother 53:139PubMedCrossRefGoogle Scholar
  3. 3.
    Imafuku Y, Omenn GS, Hanash S (2004) Proteomics approaches to identify tumor antigen directed autoantibodies as cancer biomarkers. Dis Markers 20:149PubMedGoogle Scholar
  4. 4.
    Xiao Z, Prieto D, Conrads TP, Veenstra TD, Issaq HJ (2005) Proteomic patterns: their potential for disease diagnosis. Mol Cell Endocrinol 230:95PubMedCrossRefGoogle Scholar
  5. 5.
    Mian S, Ugurel S, Parkinson E, Schlenzka I, Dryden I, Lancashire L, Ball G, Creaser C, Rees R, Schadendorf D (2005) Serum proteomic fingerprinting discriminates between clinical stages and predicts disease progression in melanoma patients. J Clin Oncol 23:5088PubMedCrossRefGoogle Scholar
  6. 6.
    Le Naour F, Misek DE, Krause MC, Deneux L, Giordano TJ, Scholl S, Hanash SM (2001) Proteomics-based identification of RS/DJ-1 as a novel circulating tumor antigen in breast cancer. Clin Cancer Res 7:3328PubMedGoogle Scholar
  7. 7.
    Canelle L, Bousquet J, Pionneau C, Deneux L, Imam-Sghiouar N, Caron M, Joubert-Caron R (2005) An efficient proteomics-based approach for the screening of autoantibodies. J Immunol Methods 299:77PubMedCrossRefGoogle Scholar
  8. 8.
    Le Naour F (2001) Contribution of proteomics to tumor immunology. Proteomics 1:1295PubMedCrossRefGoogle Scholar
  9. 9.
    Sun Z, Fu X, Zhang L, Yang X, Liu F, Hu G (2004) A protein chip system for parallel analysis of multi-tumor markers and its application in cancer detection. Anticancer Res 24:1159PubMedGoogle Scholar
  10. 10.
    Goodell V, Disis ML (2005) Human tumor cell lysates as a protein source for the detection of cancer antigen-specific humoral immunity. J Immunol Methods 299:129PubMedCrossRefGoogle Scholar
  11. 11.
    Rapkiewicz AV, Espina V, Petricoin EF, Liotta LA (2004) Biomarkers of ovarian tumours. Eur J Cancer 40:2604PubMedCrossRefGoogle Scholar
  12. 12.
    Wang X, Yu J, Sreekumar A, Varambally S, Shen R, Giacherio D, Mehra R, Montie JE, Pienta KJ, Sanda MG, Kantoff PW, Rubin MA, Wei JT, Ghosh D, Chinnaiyan AM (2005) Autoantibody signatures in prostate cancer. N Engl J Med 353:1224PubMedCrossRefGoogle Scholar
  13. 13.
    Fernández Madrid F (2005) Autoantibodies in breast cancer sera: candidate biomarkers and reporters of tumorigenesis. Cancer Lett 230:187PubMedCrossRefGoogle Scholar
  14. 14.
    Coronella-Wood JA, Hersh EM (2003) Naturally occurring B-cell responses to breast cancer. Cancer Immunol Immunother 52:715PubMedCrossRefGoogle Scholar
  15. 15.
    Lacroix M, Leclercq G (2004) Relevance of breast cancer cell lines as models for breast tumours: an update. Breast Cancer Res Treat 83:249PubMedCrossRefGoogle Scholar
  16. 16.
    de Visser KE, Coussens LM (2005) The interplay between innate and adaptive immunity regulates cancer development. Cancer Immunol Immunother 54:1143PubMedCrossRefGoogle Scholar
  17. 17.
    Wen YJ, Mancino A, Pashov A, Whitehead T, Stanley J, Kieber-Emmons T (2005) Antigen binding of human IgG fabs mediate ERK-associated proliferation of human breast cancer cells. DNA Cell Biol 24:73PubMedCrossRefGoogle Scholar
  18. 18.
    Li WH, Zhao J, Li HY, Liu H, Li AL, Wang HX, Wang J, He K, Liang B, Yu M, Shen BF, Zhang XM (2006) Proteomics-based identification of autoantibodies in the sera of healthy Chinese individuals from Beijing. Proteomics 6:4781PubMedCrossRefGoogle Scholar
  19. 19.
    Shoshan SH, Admon A (2005) Proteomics in cancer vaccine development. Expert Rev Proteomics 2:229PubMedCrossRefGoogle Scholar
  20. 20.
    Fernández-Madrid F, Tang N, Alansari H, Granda JL, Tait L, Amirikia KC, Moroianu M, Wang X, Karvonen RL (2004) Autoantibodies to annexin XI-A and other autoantigens in the diagnosis of breast cancer. Cancer Res 64:5089PubMedCrossRefGoogle Scholar
  21. 21.
    Todorova K, Ignatova I, Tchakarov S, Altankova I, Zoubak S, Kyurkchiev S, Mincheff M (2005) Humoral immune response in prostate cancer patients after immunization with gene-based vaccines that encode for a protein that is proteasomally degraded. Cancer Immun 5:1PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • Carlyle Hamsher
    • 1
  • Anna M. Smith
    • 1
  • Zia A. Dehqanzada
    • 1
  • Steven Khoo
    • 1
  • Sathibalan Ponniah
    • 1
  • George E. Peoples
    • 1
    • 2
  • Maria Moroni
    • 1
    • 3
  1. 1.Cancer Vaccine Development Laboratory, Department of SurgeryUniformed Services University of the Health SciencesBethesdaUSA
  2. 2.Department of SurgeryBrooke Army Medical CenterFort Sam HoustonUSA
  3. 3.Armed Forces Radiobiology Research InstituteUniformed Services University of the Health SciencesBethesdaUSA

Personalised recommendations